摘要
背景:在之前的纵向随访调查研究中,除了睡眠呼吸性障碍(非呼吸暂停睡眠障碍 ,NSD)的睡眠障碍,特别是失眠和白天过渡性嗜睡已经被报导出高风险引发认知减退和痴呆。然而,大型的基于全国范围内人口研究可能进一步确认NSD与痴呆的关系。 方法:这是一次以全国范围内人口为基础的回顾性研究。我们使用了台湾全民健康保险研究资料库 (NHIRD)2000年1月至2011年12月的数据。NSD组包含了92079例20岁以上无痴呆病史的病人。对照组使用倾向评分1:1匹配了92079例对照。 痴呆案例的确定在2011年底截至。多元Cox风险比例回归分析被用来评价NSD组与非NSD组调整风险比率(aHRs)。 结果:在NSD与非NSD中,痴呆的发病率分别为4.19和2.95每1000人年,aHRs为1.46(95% CI=1.38-1.54;p<0.0001),痴呆的风险在性别和全年龄分组都要高,男性和年轻人群稍微高一点,分别为(aHR: 1.48, 95% CI=1.35–1.62, p<0.0001) 和(aHR: 2.79, 95% CI=1.63–4.78, p<0.0001)。痴呆最有可能在随访的第一年发生(aHR: 1.73, 95% CI=1.49–2.02; p<0.0001),但与对照组比较,NSD诊断后的5年痴呆的风险依旧很高。 结论:NSD可能是认知功能减退的早期指标,也是短期内痴呆的发病因素。它也长期提高了患痴呆的风险。NSD病人应该需要被密切监视认知减退。
关键词: 认知障碍,痴呆,流行病学,非呼吸暂停睡眠障碍,回顾性研究,睡眠障碍
Current Alzheimer Research
Title:Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder
Volume: 14 Issue: 3
Author(s): Pi-Shan Sung, Chih-Ching Yeh, Liang-Chao Wang, Peir-Haur Hung, Chih-Hsin Muo, Fung-Chang Sung, Chih-Hung Chen, Kuen-Jer Tsai.
Affiliation:
关键词: 认知障碍,痴呆,流行病学,非呼吸暂停睡眠障碍,回顾性研究,睡眠障碍
摘要: Background: Sleep disorders other than sleep apnea (non-apnea sleep disorder, NSD), esp. insomnia and excessive daytime sleepiness, has been reported to induce higher risk of cognitive decline and dementia in previous longitudinal follow-up studies. However, large-scale nationwide populationbased study may further confirm the association between NSD and dementia.
Methods: It was a nationwide population-based retrospective study. We used data from Taiwan’s National Health Insurance Research Database (NHIRD) between January 2000 and December 2011. The NSD cohort comprised 92,079 patients aged over 20 years with no preexisting dementia. The comparison cohort was propensity-score matched 1:1 with 92079 controls. Incident dementia cases were identified to the end of 2011. The NSD cohort to non-NSD cohort adjusted hazard ratios (aHRs) of dementia were assessed using multivariable Cox proportional hazards regression analysis. Results: Incidence of dementia was 4.19 and 2.95 per 1,000 person-years in the NSD and non-NSD cohorts, respectively, with an aHR of 1.46 (95% CI=1.38–1.54; p<0.0001). Risk of dementia was higher in both gender and whole age subgroup, with slightly higher in men (aHR: 1.48, 95% CI=1.35–1.62, p<0.0001) and in the younger population (aHR: 2.79, 95% CI=1.63–4.78, p<0.0001). Dementia was most likely to occur in the first year of follow-up (aHR: 1.73, 95% CI=1.49–2.02; p<0.0001), but dementia risk remained high 5 years after NSD diagnosis compared to controls (aHR: 1.44, 95% CI=1.32–1.57; p<0.0001). Conclusion: NSD may be an early indicator of decline in cognitive functioning and onset of dementia in the short-term period. It also carries a higher risk for dementia in the long run. Patients with NSD should require close monitoring for cognitive decline.Export Options
About this article
Cite this article as:
Pi-Shan Sung, Chih-Ching Yeh, Liang-Chao Wang, Peir-Haur Hung, Chih-Hsin Muo, Fung-Chang Sung, Chih-Hung Chen, Kuen-Jer Tsai. , Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder, Current Alzheimer Research 2017; 14 (3) . https://dx.doi.org/10.2174/1567205013666161108104703
DOI https://dx.doi.org/10.2174/1567205013666161108104703 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transcranial Direct Current Stimulation for Treatment of Alzheimer’s Disease: A Systematic Review of Randomized Clinical Trial
Current Psychiatry Reviews Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Amyloid-β Immunotherapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Synthesis, Molecular Targets, and Antitumor Activities of Substituted Tetrahydro-1- Oxopyrano[4,3-b][1]Benzopyrans and Nanogels for Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design Protection by Nigella Sativa [Black Seed] against Hyperhomocysteinemia in Rats
Vascular Disease Prevention (Discontinued) Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
Current Alzheimer Research Inflammatory Cytokines in Acute Ischemic Stroke
Current Pharmaceutical Design Solution NMR Studies of Aβ Monomer Dynamics
Protein & Peptide Letters The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery Pharmacogenomics in Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Testosterone and Cognition in Normal Aging and Alzheimers Disease: An Update
Current Alzheimer Research Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Structural Characterization of Amyloid β17-42 Dimer by Potential of Mean Force Analysis: Insights from Molecular Dynamics Simulations
Protein & Peptide Letters Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Lobar Atrophy in Frontotemporal Dementia: Diagnostic and Prognostic Implications
Current Alzheimer Research Snapshots of Protein Folding Problem: Implications of Folding and Misfolding Studies
Protein & Peptide Letters Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Mechanisms of HIV-1 Neurotropism
Current HIV Research Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design